Comparative Pharmacology
Head-to-head clinical analysis: DARUNAVIR ETHANOLATE versus EVOTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARUNAVIR ETHANOLATE versus EVOTAZ.
DARUNAVIR ETHANOLATE vs EVOTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits the cleavage of HIV-encoded Gag-Pol polyproteins in infected cells, thereby preventing the formation of mature infectious virus particles.
EVOTAZ is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor, and cobicistat, a CYP3A inhibitor. Atazanavir inhibits HIV-1 protease, preventing cleavage of viral polyproteins and resulting in immature, non-infectious virions. Cobicistat increases systemic exposure of atazanavir by inhibiting CYP3A-mediated metabolism.
600 mg orally twice daily with ritonavir 100 mg twice daily, or 800 mg orally once daily with ritonavir 100 mg once daily and with food.
1 tablet (300 mg atazanavir and 150 mg cobicistat) orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours when coadministered with ritonavir (100 mg), and about 5-6 hours without booster. Clinical context: allows once-daily or twice-daily dosing with boosting.
Cobicistat: terminal half-life approximately 3–4 hours; atazanavir: terminal half-life approximately 7 hours (range 5–12 hours) at steady state when boosted with cobicistat. The short half-life of cobicistat necessitates once-daily dosing with atazanavir to maintain therapeutic concentrations.
Primarily hepatic metabolism via CYP3A4, followed by biliary excretion of metabolites; renal excretion of unchanged drug is minimal (<10%). In feces, approximately 79% of dose is recovered as metabolites; in urine, <10% as unchanged drug.
Cobicistat: primarily hepatic metabolism (CYP3A4) and biliary/fecal excretion; <7% excreted unchanged renally. Atazanavir: primarily biliary/fecal excretion as unchanged drug and metabolites (79–88%); renal excretion accounts for <7%.
Category A/B
Category C
Protease Inhibitor
Protease Inhibitor